What Happens When We Are Blinded by Left Main Disease and Ignore All Other Lesions?

According to this recent Excel analysis, mortality seems to rise when the SYNTAX II score is not taken into account when defining the revascularization strategy. The difference does not reach statistical significance and further studies are required, but the message is clear: the left main coronary artery is not the only thing that matters; other lesions should be considered as well, particularly because they may occasionally tilt the scales in cases when left main disease is resolved with a simple angioplasty. All of this was presented by Dr. Patrick Serruys at the most recent PCR scientific sessions.

The SYNTAX II score derives from the original SYNTAX trial and it was developed to predict long-term mortality after left main and multivessel revascularization. SYNTAX II combines anatomic lesion data, included in the original score, and clinical characteristics such as age, sex, chronic obstructive pulmonary disease, peripheral vascular disease, ejection fraction, or creatinine clearance.

Noncompliance with the score’s recommendation indicating that the patient could benefit more from a surgical strategy (therefore treating the patient with angioplasty) was associated with a trend toward higher all-cause mortality at 4 years.

The main EXCEL study included 1900 low-to-moderate risk patients with unprotected left main lesions who were randomized to angioplasty or surgery. At 3 years, results for both strategies were comparable in terms of death, stroke, or infarction.


Read also: Prosthetic Valve Endocarditis and TAVR: though Rare, Devastating.


This new analysis included 1807 patients from EXCEL who had a SYNTAX II score. Among patients whose SYNTAX II score suggested surgery as the best option, only 78 were randomized to surgery while 81 underwent angioplasty.

Similarly, among patients whose score suggested angioplasty as the best option, 184 underwent surgery and 158, angioplasty. Overall, the concordance rate between SYNTAX II score recommendations and treatment strategy was 85%.

In patients whose score recommendation matched treatment, 4-year mortality was not significantly different between strategies (9% vs. 7.5%; hazard ratio [HR]: 1.19; 95% confidence interval [CI]: 0.81-1.75).

However, results were markedly different for patients whose score recommendation did not match the treatment strategy. When the SYNTAX II score recommended surgery, 4-year mortality was 5.3% in those randomized to surgery vs. 14.1% in those randomized to angioplasty (p = 0.07).


Read also: Antianginal Medication Before and After Rechanneling.


In the group for whom the score recommended angioplasty, short-term mortality was much higher with surgery (5% vs. 0% at 6 months with angioplasty). However, at 4 years, the curves intersected, but differences remained non-significant (13.6% for angioplasty vs. 7.8% for surgery, p = 0.11).

The low number of patients for whom randomization did not match score recommendation means that this analysis is underpowered to detect differences. However, it helps us prevent potential mistakes and it warns us against forcing indications.

Original title: Non-respect of SYNTAX score II treatment recommendation of surgery (PCI treated) negatively impacts 4-year mortality in patients with LM CAD—the EXCEL trial.

Reference: Serruys P et al. Presentado en el EuroPCR 2019.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...